Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
Arun Azad(Peter MacCallum Cancer Centre), Kim N.(Asian Institute of Technology), Renee Lester(Baker Hughes (Canada)), Bernhard J. Eigl(BC Cancer Agency), Daniel Yick Chin Heng(University of Calgary)
Cited by 5
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k